DBV Technologies (NASDAQ:DBVT) Price Target Raised to $45.00 at Citizens Jmp

DBV Technologies (NASDAQ:DBVT) had its price target hoisted by stock analysts at Citizens Jmp from $21.00 to $45.00 in a research note issued to investors on Wednesday,Benzinga reports. The firm presently has a “market outperform” rating on the stock. Citizens Jmp’s price target points to a potential upside of 150.28% from the company’s current price.

DBVT has been the topic of several other reports. Citigroup restated an “outperform” rating on shares of DBV Technologies in a research report on Wednesday. Guggenheim reissued a “buy” rating and set a $51.00 price objective (up previously from $35.00) on shares of DBV Technologies in a research report on Wednesday. Zacks Research upgraded shares of DBV Technologies from a “strong sell” rating to a “hold” rating in a report on Monday, September 29th. HC Wainwright reiterated a “buy” rating and issued a $35.00 price target (up from $20.00) on shares of DBV Technologies in a research note on Monday. Finally, Wall Street Zen raised shares of DBV Technologies from a “sell” rating to a “hold” rating in a research note on Friday, November 28th. Two investment analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, DBV Technologies has a consensus rating of “Moderate Buy” and an average target price of $33.54.

DBV Technologies Stock Performance

DBV Technologies stock opened at $17.98 on Wednesday. DBV Technologies has a fifty-two week low of $2.74 and a fifty-two week high of $21.50. The stock’s 50 day simple moving average is $14.98 and its two-hundred day simple moving average is $11.58. The stock has a market cap of $722.08 million, a price-to-earnings ratio of -3.48 and a beta of -1.10.

Hedge Funds Weigh In On DBV Technologies

Hedge funds have recently bought and sold shares of the company. Millennium Management LLC increased its stake in DBV Technologies by 26.1% during the 3rd quarter. Millennium Management LLC now owns 337,863 shares of the company’s stock valued at $3,379,000 after purchasing an additional 69,849 shares in the last quarter. Citadel Advisors LLC purchased a new stake in shares of DBV Technologies during the third quarter valued at approximately $220,000. Two Sigma Investments LP bought a new stake in shares of DBV Technologies during the third quarter valued at approximately $167,000. DLD Asset Management LP bought a new stake in shares of DBV Technologies during the third quarter valued at approximately $250,000. Finally, Artisan Partners Limited Partnership bought a new position in DBV Technologies in the 3rd quarter valued at approximately $519,000. Institutional investors own 71.74% of the company’s stock.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.